Share price · RDY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RDY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Jul 2026-9.4%
- 29 Jun 2026-3.4%
- Day beforeDr. Reddy's Laboratories: 6-K filing
- 14 May 2026+3.8%
Nothing announced by RDY that day or the session before.
- 12 May 2026-5.2%
- 23 Apr 2026+5.8%
Nothing announced by RDY that day or the session before.
- 1 Apr 2026-2.7%
Nothing announced by RDY that day or the session before.
Share of unusual movement by asset
For each asset, the share of RDY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Olutasidenibevents and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 54% |
| Sessions with no dated event | — | 46% |
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | COX-2Small molecule | Migraine | |
| Approved | Mutant IDH1Small molecule | Acute Myeloid LeukemiaGlioma Relapsed/Refractory Acute Myeloid Leukemia | |
| Phase 3 | CD38Monoclonal antibody | Multiple Myeloma | |
| Phase 3 | EGFR/HER1, HER2, HER4Small molecule | Non-Small Cell Lung CancerBreast Cancer HER2-Positive Breast Cancer |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (2)
2029 (1)
June 2029 (1)
What to watch
2030 (1)
September 2030 (1)
What to watch
Financial reports
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.8B | $323M | $172M | —$548M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
No Form 4 transactions on file in the stored window.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 245 reporting institutions held 120.4M shares ($1.6B, 14.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Robeco Institutional Asset Management B.V. | 17,177,882 | $237.9M |
| 2 | BlackRock, Inc. | 11,587,127 | $160.5M |
| 3 | ROYAL BANK OF CANADA | 9,984,082 | $138.3M |
| 4 | MORGAN STANLEY | 9,371,594 | $129.8M |
| 5 | Aikya Investment Management Ltd | 7,999,796 | $110.8M |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 7,859,728 | $108.9M |
| 7 | DIMENSIONAL FUND ADVISORS LP | 5,323,248 | $73.7M |
| 8 | JPMORGAN CHASE & CO | 4,371,378 | $58.8M |
| 9 | STATE STREET CORP | 4,026,207 | $55.8M |
| 10 | BNP PARIBAS FINANCIAL MARKETS | 3,183,971 | $44.1M |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 3,100,911 | $42.9M |
| 12 | FRANKLIN RESOURCES INC | 2,856,094 | $39.6M |
| 13 | MARSHALL WACE, LLP | 2,664,306 | $36.9M |
| 14 | ALLIANCEBERNSTEIN L.P. | 2,541,889 | $35.7M |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,773,738 | $24.6M |